EU Clinical Trials Register
Herr Prof. Dr. med. Martin Dreyling
Klinikum der Universität München
New phase III clinical study with tazemetostat for patients with relapsed/refractory follicular lymphoma Tazemetostat - orally administered, first-in-class small molecule EZH2 inhibitor
